Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05460273 · OUTCOME

Best Overall Response (BoR) , Assessed by ICR

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02) · Source last updated 2026-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage
Interval / dispersion
Not reported
Time frame
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.

What was measured

Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.

Analysis population: RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.

Groups in this outcome

TNBC Cohort

Final Analysis with DCO on 06May2024

NSCLC Cohort

Final Analysis with DCO on 27Nov2024

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TNBC Cohort77
NSCLC Cohort40

Reported measurements

Confirmed Partial Response
Values in Percentage · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TNBC Cohort33.8Not reportedNot reportedNot reportedNot reported
NSCLC Cohort45.0Not reportedNot reportedNot reportedNot reported
Confirmed Complete Response
Values in Percentage · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TNBC Cohort0Not reportedNot reportedNot reportedNot reported
NSCLC Cohort0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        33.8
      2. group Id
        OG001
        value
        45.0
    title
    Confirmed Partial Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
    title
    Confirmed Complete Response
denoms
  1. counts
    1. group Id
      OG000
      value
      77
    2. group Id
      OG001
      value
      40
    units
    Participants
description
Best overall response is defined as participant's best confirmed response during their participation in the study, but prior to starting any subsequent anticancer therapy, up until RECIST 1.1-defined PD or the last evaluable assessment in the absence of RECIST 1.1-defined progression.
groups
  1. description
    Final Analysis with DCO on 06May2024
    id
    OG000
    title
    TNBC Cohort
  2. description
    Final Analysis with DCO on 27Nov2024
    id
    OG001
    title
    NSCLC Cohort
param Type
NUMBER
population Description
RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR.
reporting Status
POSTED
time Frame
TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.
title
Best Overall Response (BoR) , Assessed by ICR
type
SECONDARY
unit Of Measure
Percentage

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice